Yazar "Arican, M." seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • [ X ]
    Öğe
    Clinical Experience of Interlocking Nail Stabilization of Long Bone Fractures in Dogs - A Retrospective Study of 26 Cases
    (Israel Veterinary Medical Assoc, 2017) Arican, M.; Alkan, F.; Altan, S.; Parlak, K.; Yavru, N.
    The aim of the study is to report the clinical and radiographic outcome after use of an interlocking nail (ILN) for stabilization of long bone fractures in dogs. Twenty-six dogs were evaluated. There were ten femoral fractures, 12 tibial fractures and four humeral fractures. The equipment was manufactured by Orthovet (Orthovet, Izmir, Turkey). Three ILN lengths with three different diameters (4, 6 and 8 mm) were used. Each ILN had a trocar tip on one end and four screw holes (two distal and two proximal). Ten fractures (four femoral, five tibial, one humeral) were associated with other orthopedic problems. Nine (39.1%) patients had aseptic nonunion and malunion fractures. A static fixation mode was used for nine fractures and a dynamic fixation mode was used in 17 (65.3%). The surgical time recorded was 45-52 minutes. Three dogs had a major complication requiring surgical intervention. At 6 months, the functional outcome was excellent in 15 (57.6%) animals, good in seven (26.9%), fair in three (11.5%), and poor in one (3.8). In conclusion, the use of ILNs to repair diaphyseal fractures of the femur, tibia, and humerus in dogs resulted in a good or excellent functional outcome in most patients.
  • [ X ]
    Öğe
    Plasma and synovial fluid pharmacokinetics of cefquinome following the administration of multiple doses in horses
    (Wiley, 2017) Uney, K.; Altan, F.; Altan, S.; Erol, H.; Arican, M.; Elmas, M.
    The plasma and synovial fluid pharmacokinetics and safety of cefquinome, a 2-amino-5-thiazolyl cephalosporin, were determined after multiple intravenous administrations in sixteen healthy horses. Cefquinome was administered to each horse through a slow i.v. injection over 20min at 1, 2, 4, and 6mg/kg (n=4 horses per dose) every 12h for 7days (a total of 13 injections). Serial blood and synovial fluid samples were collected during the 12h after the administration of the first and last doses and were analyzed by a high-performance liquid chromatography assay. The data were evaluated using noncompartmental pharmacokinetic analyses. The estimated plasma pharmacokinetic parameters were compared with the hypothetical minimum inhibitory concentration (MIC) values (0.125-2g/mL). The plasma and synovial fluid concentrations and area under the concentration-time curves (AUC) of cefquinome showed a dose-dependent increase. After a first dose of cefquinome, the ranges for the mean plasma half-life values (2.30-2.41h), the mean residence time (1.77-2.25h), the systemic clearance (158-241mL/h/kg), and the volume of distribution at steady-state (355-431mL/kg) were consistent across dose levels and similar to those observed after multiple doses. Cefquinome did not accumulate after multiple doses. Cefquinome penetrated the synovial fluid with AUC(synovial fluid)/AUC(plasma) ratios ranging from 0.57 to 1.37 after first and thirteenth doses, respectively. Cefquinome is well tolerated, with no adverse effects. The percentage of time for which the plasma concentrations were above the MIC was >45% for bacteria, with MIC values of 0.25, 0.5, and 1g/mL after the administration of 1, 2, and 4 or 6mg/kg doses of CFQ at 12-h intervals, respectively. Further studies are needed to determine the optimal dosage regimes in critically ill patients.